Related Experiment Video
Updated: Aug 17, 2025
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
The initial experience with the Embotrap III stent-retriever in a real world setting
Osama Omrani1, Nema Hafezi-Bakhtiari1, Peter DeSouza2
1Department of Radiology, The Royal London Hospital, Barts NHS Trust, London, UK.
Materials And Methods:
We performed a retrospective review of our prospectively maintained database to identify all patients treated with the Embotrap 3 stent-retriever between January 2021 and January 2022. We recorded the baseline demographics, NIHSS, ASPECT score and clot characteristics, first pass and final eTICI scores, complications and 90 day mRS.
Results:
One hundred and ten patients met the inclusion criteria, average age 69 ± 14 years, 50% were male (n = 55). The median NIHSS at presentation was 18 (range 3-30) and 58.2% received IV tPA prior to MT. The median ASPECT score on plain CT was 8 with average clot length 20.2 ± 14.8 mm (n = 93). The first pass effect (FPE) was seen in 41.8% of cases with modified FPE seen in 59.1%. A 24-hour CT scan (n = 97) showed median ASPECTs of 7. 43.8% of patients achieve mRS ≤ 2 at 90-day mRS (n = 64).
Conclusion:
The Embotrap 3 stent-retriever has a high rate of FPE and final recanalization in this real world cohort of patients.
